Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
ATR · against 177 other Healthcare companies of similar size
Ranked #47 of 178 · scores higher than 72% of peers
Bars: peers in each 10-point band of the valuation score27 peers with a valuation score of 60–69, including ATR · Click a bar to see the companies
Mainly thanks to its EBITDA yield, free cash flow yield and earnings yield, which are stronger than most Healthcare peers.
| Metric | ATR | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 177 reported | 3.9% | 2.5% | 71% | 30% | |
| EBITDA yieldHigher is better · 177 reported | 7.7% | 4.7% | 78% | 50% | |
| Free cash flow yieldHigher is better · 105 reported | 3.6% | 1.8% | 71% | 20% | |
| Book yieldHigher is better · 177 reported | 29.0% | 19.5% | 64% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 37.3B HKD (≈$4.8B) | 99 | 90 | |
| 3 | 89.5B HKD (≈$11.5B) | 98 | 67 | |
| 4 | 10.4B USD | 96 | 64 | |
| 5 | 80.2B CNY (≈$11.2B) | 95 | 76 | |
| 40 | 14.9B EUR (≈$16.4B) | 71 | 52 | |
| 40 | 10.9B EUR (≈$11.9B) | 71 | 59 | |
| 45 | 11.6B USD | 70 | 56 | |
| 45 | 4.6B USD | 70 | 61 | |
| 47 | 9.0B USD | 69 | 57 | |
| 47 | 9.2B USD | 69 | 47 | |
| 47 | 4.8B USD | 69 | 52 | |
| 47 | 5.2B CHF (≈$5.9B) | 69 | 69 | |
| 51 | 13.9B EUR (≈$15.3B) | 68 | 78 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score